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TWEAK is a recently cloned novel member of the TNF ligand family. Here we show that solu-
ble TWEAK is sufficient to induce apoptosis in Kym-1 cells within 18 h. TWEAK-induced
apoptosis is indirect and is mediated by the interaction of endogenous TNF and TNF recep-
tor (TNFR)1, as each TNFR1-Fc, neutralizing TNF-specific antibodies and TNFR1-specific
Fab fragments efficiently antagonize cell death induction. In addition to this indirect mode of
action, co-stimulation of Kym-1 cells with TWEAK enhances TNFR1-mediated cell death
induction. In contrast to TNF, TWEAK does only modestly activate NF- O B or c-jun N-terminal
kinase (JNK) in Kym-1 cells. Although TWEAK binding to Kym-1 cells is easily detectable by
flow cytometric analysis, we found neither evidence for expression of the recently identified
TWEAK receptor Apo3/TRAMP/wsl/DR3/LARD, nor indications for direct interactions of
TWEAK with TNFR. Together, these characteristics of TWEAK-induced signaling in Kym-1
cells argue for the existence of an additional, still undefined non-death domain-containing
TWEAK receptor in Kym-1 cells.
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1 Introduction
The members of the TNF ligand family mediate various
biological effects including apoptosis, differentiation and
inflammatory responses [1, 2]. Most ligands of this family
are primarily expressed as type II membrane proteins,
but for many of these cytokines, soluble forms can be
released by proteolytic processing [2]. These ligands
exert their biological functions by binding to one or more
members of a complementary family of receptors, which
form the TNFR superfamily [1, 2]. This receptor family is
characterized by the presence of several cysteine-rich
motifs of about 40 amino acids in the extracellular
domains [1, 2]. The intracellular domains of these recep-
tors are more heterogeneous and show little sequence
similarity, except in a subgroup of the TNFR that induce
apoptosis via an intracellular death domain motif [3].
Members of this subgroup are believed to engage the
apoptotic machinery via cytoplasmic death domain-
containing adaptor molecules like TRADD [4], FADD/
MORT [5, 6] and RAIDD [7] that in turn recruit caspases
with large regulatory domains like caspase-2, -8 and -10
[7–10]. With regard to signaling mechanisms, the most
prominent feature of the other non-death domain-
containing members of the TNFR superfamily is their
binding to members of the TNFR-associated factor
(TRAF) family leading to NF- O B and c-jun N-terminal
kinase (JNK) activation [11]. Nevertheless, induction of
apoptosis by non-death domain-containing members of
the TNFR superfamily has also been described although
the underlying mechanisms are still poorly understood
[12–15]. TWEAK/Apo3L is a novel member of the TNF
ligand family that weakly induces apoptosis, mediates
chemokine induction, activates NF- O B and indudcs pro-
liferation in endothelial cells [16–18]. In a recent study,
the orphan death domain-containing receptor Apo3/wsl/
TRAMP/DR3/LARD [19–23] has been identified as a
receptor for TWEAK [17]. Here, we show that TWEAK-
induced apoptosis critically depends on the autocrine/
paracrine action of induced TNF. Moreover, as the
response pattern of TWEAK in Kym-1 cells is quite dis-
tinct from that of TNF and as we have obtained no evi-
dence for Apo3/TRAMP expression, we propose the
existence of another TWEAK receptor distinct from
Apo3/TRAMP.
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Figure 1. Characterization of recombinant FLAG-tagged soluble TWEAK. (A) SDS-PAGE analysis of purified sTWEAK with and
without PNGase F treatment. Molecular masses (kDa) of standards are indicated. (B) Gel filtration analysis of sTWEAK. sTWEAK-
containing supernatants were concentrated and loaded onto a Superdex 200 column. Fractions were analyzed for the presence
of sTWEAK by Western blotting using the FLAG-specific mAb M2. Elution volumes of various molecular mass standards are indi-
cated.
2 Results and discussion
2.1 Characterization of recombinant TWEAK
The extracellular domain of human TWEAK was
expressed in human embryonic kidney 293 cells as a sol-
uble, FLAG-tagged and N-glycosylated cytokine
(sTWEAK). Treatment of sTWEAK with peptide N-
glycanase F (PNGaseF) induced a shift in molecular
mass from 23 to 19 kDa, indicating that the unique puta-
tive N-glycosylation site predicted from the primary
sequence of TWEAK is indeed utilized (Fig. 1A). sTWEAK
displayed a molecular mass of about 63 kDa when ana-
lyzed by gel permeation chromatography (i. e. 2.7 times
the size of the monomer), suggesting that sTWEAK is a
homotrimer under native conditions (Fig. 1B). This is in
agreement with crystallographic data demonstrating that
other members of the TNF family (TNF, lymphotoxin §
and CD40L) are homotrimers [24–26]. Purified sTWEAK
was able to induce cell death in the human colon carci-
noma cell line HT-29 when added simultaneously with
IFN- + , and this cytotoxicity could not be further
increased by cross-linking of sTWEAK ([16, 27] and data
not shown). This is in contrast with some other ligands of
the TNF family, like FasL and TRAIL, which become up to
1000-fold more active when cross-linked [27]. Taken
together, these date indicate that sTWEAK is most prob-
ably active as a homotrimer.
2.2 TWEAK induces cell death in Kym-1 cells via
endogenous TNF/TNFR1 interaction
We have screened several cell lines for their sensitivity to
sTWEAK and found that Kym-1 cells, a rhabdomyosar-
coma cell line, was efficiently killed by sTWEAK, whether
or not sTWEAK was cross-linked by anti-FLAG anti-
bodies (Fig. 2A). These data indicate that mere trimeriza-
tion of TWEAK receptors is sufficient for the initiation of
the apoptotic program in Kym-1 cells. The kinetics of
apoptosis induction by sTWEAK in Kym-1 cells was
slower than that induced by TNF, but similar to that
observed in the same cells upon triggering of TNFR2
(Fig. 2B). Kym-1 cells are indeed one of the rare cellular
models in which apoptosis can be induced by exclusive
triggering of each of both TNFR [15]. We have recently
found that the apoptotic response initiated by agonistic
TNFR2-specific antibodies was based on the induction
of expression of endogenous transmembrane TNF that
in turn kills Kym-1 cells by acting on TNFR1 via an auto-
crine/paracrine loop (manuscript in preparation). As a
consequence of this indirect mechanism of action, the
onset of TNFR2-initiated apoptosis is significantly
delayed compared to that mediated by TNFR1 (Fig. 2B).
The same delay in the onset of apoptosis was observed
when sTWEAK was added to the cells (Fig. 2B). To test
whether a similar indirect mechanism of apoptosis could
also be initiated by sTWEAK, we included in the assay
various agents antagonizing TNF action. sTWEAK-
induced apoptosis was completely abrogated by either
the extracellular domain of TNFR1 fused to the Fc por-
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Figure 2. TWEAK induces cell death in Kym-1 cells via endogenous TNF and TNFR1. (A) Kym-1 cells (1 × 104) were cultured over-
night in 96-well assay plates. The next day cells were treated with the indicated concentrations of sTWEAK alone (open circles)
or complexed with the aggregating antibody M2, cultivated overnight and analyzed for viability using the MTT procedure. (B)
Kym-1 cells (1 × 104) were cultured overnight in 96-well assay plates. The next day cells were treated with the indicated concen-
trations of sTWEAK (100 ng/ml, filled triangles), the agonistic TNFR2-specific antibody MR2-1 (1 ? g/ml, open triangles) or TNF
(10 ng/ml, open circles) for the indicated time and finally analyzed for viability using the MTT procedure. (C, D) Kym-1 cells were
treated with the indicated concentrations of sTWEAK in the presence (filled squares) or absence (open squares) of TNFR1-Fc (C,
5 ? g/ml) and TNFR1-specific Fab fragments (D, 20 ? g/ml), respectively, and finally analyzed for viability using the MTT procedure.
tion of human IgG1, TNFR1-Fc (but not by TRAIL-R2-Fc;
data not shown), TNFR1-specific Fab fragments and
neutralizing TNF-specific antibodies (Figs. 2C, D and
3A). This endogenous TNF is probably membrane
bound, because the supernatants of sTWEAK-treated
Kym-1 cells were non-toxic for the TNF-sensitive WEHI-
164 cell line, indicating that no significant amounts of
soluble (s)TNF were produced in response to sTWEAK
(data not shown). Preliminary data indicate, however,
that sTWEAK/IFN- + killing of HT-29 cells [16] is not inhib-
ited by TNFR1-Fc (data not shown), pointing to the exis-
tence of an alternative mechanism of apoptosis induc-
tion by sTWEAK. Nevertheless, indirect apoptosis induc-
tion via TNF and TNFR1 has also been reported to occur
after TNFR2 stimulation and may thus represent a rather
general mechanism by which non death-domain recep-
tors trigger apoptosis ([28], manuscript in preparation).
2.3 TWEAK enhances TNFR1-mediated cell
death
Triggering of TNFR2 not only leads to TNF induction but
also to a marked enhancement of TNFR1-induced apop-
tosis via an intracellular mechanism which most likely
relies on the inactivation of TRAF2, leading to the abro-
gation of TNFR1-mediated induction of anti-apoptotic
factors [29, 30]. We have therefore analyzed whether
sTWEAK treatment results in a similar sensitization
towards TNFR1-induced apoptosis. For this purpose,
the effect of sTWEAK-induced, endogenously produced
TNF was neutralized using TNF-specific antibodies. In
addition, TNFR1 was stimulated with an agonistic
TNFR1-specific antibody at a concentration that induces
no or only very limited apoptosis on its own. As shown in
Fig. 3B, neither the lowest concentration of the agonistic
TNFR1-specific antibody Htr-1 alone nor the combina-
tion of sTWEAK and anti-TNF antibodies induced signifi-
cant cell death in Kym-1 cells. However, when Htr-1 and
sTWEAK plus anti-TNF antibodies were applied, a strong
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Figure 3. TWEAK enhances TNFR1-mediated cell death in Kym-1 cells. (A) Kym-1 cells were treated with 200 ng/ml sTWEAK in
the presence or absence of TNFR1-Fc (5 ? g/ml) and neutralizing TNF-specific antibodies (30 ? g/ml) and finally analyzed for viabil-
ity using the MTT procedure. (B) Kym-1 cells were incubated with the indicated concentrations of the TNFR1-specific agonistic
mAb Htr-1 in the presence (hatched bars) or absence (open bars) of a non-apoptosis-inducing combination of sTWEAK (100 ng/
ml) and neutralizing anti-TNF Ab (30 ? g/ml). Cell viability was determined the next day using the MTT procedure. (C) Kym-1 cells
were treated with the indicated concentration of TNF in the presence (filled squares) and absence (open squares) of 200 ng/ml
sTWEAK. After 4 h cell viability was determined using the MTT procedure. (D) Kym-1 cells were incubated with 1 ng/ml TNF,
200 ng/ml sTWEAK, the TNF-R2-specific mAb MR2-1 (1 ? g/ml) or combinations thereof and photographs were taken after the
indicated time periods.
apoptotic response could be observed. This observed
synergism indicates that the TWEAK receptor, similar to
TNFR2, is able to enhance TNFR1-induced apoptosis in
Kym-1 cells (Fig. 3B). An enhancement of TNFR1-
mediated cell death by co-stimulation with sTWEAK is
also shown in a different experimental setting, devoid of
TNF-neutralizing reagents. While neither low doses of
soluble TNF (1 ng/ml), that almost exclusively trigger
TNFR1 [31, 32], nor stimulation of Kym-1 cells with ago-
nistic TNFR2-specific mAb or sTWEAK resulted in signi-
ficant signs of cell death within 4–8 h after treatment, co-
stimulation of TNFR1 together with either TNFR2 or
sTWEAK caused pronounced cell death (Fig. 3C, D). We
can rule out that sTWEAK acts via binding to TNFR2 as
TNFR2-specific Fab fragments had no impact on
sTWEAK-mediated apoptosis and because sTWEAK did
not bind to TNFR2-Fc (data not shown). Taken together,
these results suggest that sTWEAK engages a receptor
on Kym-1 cells that is not directly linked to the apoptotic
caspase cascade and therefore is most likely distinct
from the death domain-containing receptor Apo3/
TRAMP. Since Apo3/TRAMP has recently been reported
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Figure 4. Lack of evidence for Apo3/TRAMP signaling in Kym-1 cells upon TWEAK treatment. (A, B, C) Kym-1 cells bind
sTWEAK but show not detectable amounts of Apo3/TRAMP expression. Kym-1 cells were incubated with FLAG-tagged TWEAK
and FLAG-tagged Fas ligand (FasL) as a control. After several washes the cells were incubated with the FLAG-specific antibody
M2 followed by a FITC-labeled rabbit anti-mouse antisera to detect bound FLAG-tagged ligands (A). (B) Western blot analysis of
Apo3/TRAMP expression in Kym-1 cells. Lysate and insoluble pellet of 1 × 105 Kym-1 cells were treated with or without PNGaseF
as described in Sect. 4.6 and analyzed for Apo3/TRAMP expression with two different Apo3/TRAMP-specific antisera (anti-
TRAMP NT, anti-TRAMP-CT) by Western blotting. As a control extracts of Apo3/TRAMP-transfected 293T cells were diluted in
untransfected 293T extracts and analyzed on the same gel. The amounts of TRAMP in these controls had been previously deter-
mined on a separate Western blot by comparison with known amounts of TRAMP-Fc (data not shown). (C) RNase protection
assay analysis of steady-state levels of various apoptosis-relevant molecules including Apo3/TRAMP. Total RNA (10 ? g) was ana-
lyzed with the hApo-3c Multi-Probe template set to detect caspase-8, FasL, Fas, DcR1, Apo3/DR3/TRAMP, DR4, DR5, TRAIL,
TNF-R1, TRADD, RIP and L32 and GAPDH as internal controls. Protected probes were resolved by electrophoresis on a denatur-
ing polyacrylamide gel and quantified by phosphorimaging (B). (D, E) TNF but not sTWEAK is a potent inducer of NF- O B and JNK
in Kym-1 cells. Kym-1 cells (1 × 106) were treated with 10 ng/ml TNF or 200 ng/ml sTWEAK for the indicated period of time and
were subsequently analyzed for NF- O B activation by EMSA (D) or JNK activity by immunocomplex kinase assays (E).
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to bind to TWEAK [17], we next tested whether Kym-1
cells would express this receptor. Although we could
demonstrate significant sTWEAK binding on Kym-1 cells
by FACS analysis (Fig. 4A), we obtained no indication for
Apo3/TRAMP expression in this cell line using either two
different Apo3/TRAMP-specific antisera in Western blot-
ting experiments (Fig. 4B) or RNase protection assays
(Fig. 4C). Kym-1 cell equivalents (1 × 105) were analyzed
by Western blotting. The detection limits of the Apo3/
TRAMP-specific antisera were about 0.4 ng (Fig. 4B), cor-
responding to a detection limit of 1200 TRAMP molecules
per cell. Overexpression of Apo3/TRAMP results in a pro-
nounced activation of NF- O B [19–23] and JNK (data not
shown) in several cell lines. However, there was no signifi-
cant response found in this regard in sTWEAK-treated
Kym-1 cells (Fig. 4D, E). Taken together these results sug-
gest that Apo3/TRAMP is not expressed in Kym-1 cells.
3 Concluding remarks
We have shown that sTWEAK induces TNF expression in
Kym-1 cells and at the same time sensitizes TNFR1 to the
cytotoxic effects of TNF. sTWEAK is therefore not cyto-
toxic on its own in this model but only helps to provide
factors allowing for autocrine/paracrine killing of the cells
via TNF and TNFR1. Triggering of the TWEAK receptor
does not significantly activate NF- O B or JNK pathways.
None of these results would have been predicted from
what we know so far about the death domain-containing
receptor Apo3/TRAMP. Because of these results and
because we found no evidence for Apo3/TRAMP expres-
sion in Kym-1 cells, we predict that Kym-1 cells express
a TWEAK receptor distinct from Apo3/TRAMP that is
devoid of an intracellular death domain.
4 Materials and methods
4.1 Antibodies
The TNFR2-specific antibody MR2-1 was a gift from W.
Buurman, University of Limburg, Maastricht, The Nether-
lands. The TNFR1- and TNFR2-specific Fab fragments are
derived from the mAb H398 and a polyclonal TNFR2-
specific rabbit IgG fraction is described elsewhere [31]. The
agonistic TNFR1-specific mAb Htr-1 was a gift from W.
Lesslauer, Hoffmann-La Roche Ltd., Basel and TNF was a
gift from I.-M. von Broen, Knoll AG, Ludwigshafen, Germany.
The anti-human TNF mAb (357-101-4) was provided by A.
Meager, National Institute for Biological Standards and Con-
trol, Potters Bar, GB. The Apo3/TRAMP-specific polyclonal
rabbit serum anti-TRAMP NT (AL104) raised against a pep-
tide comprising amino acid residues 1-23 of the mature pro-
tein was described elsewhere [20]. The Apo3/TRAMP-
specific polyclonal rabbit serum anti-TRAMP CT raised
against a peptide of the C-terminal part of Apo3/TRAMP
was from Millenium Biotechnology (Ramona, CA).
4.2 Purification of TWEAK
sTWEAK was produced as described [27]. Briefly, the extra-
cellular domain of human TWEAK (coding for amino acids
106-249) was subcloned in a modified version of the PCR-III
vector (Invitrogen, NV Leek, The Netherlands), in frame with
the hemagglutinin signal peptide and a FLAG epitope. Con-
ditioned supernatants of stably transfected 293 cells were
harvested after 14 days of culture. FLAG-tagged sTWEAK
was purified on M2-agarose (Sigma) and eluted in 50 mM
citrate-NaOH, pH 2.5, followed by neutralization with Tris-
HCl pH 8. The buffer was exchanged to PBS and the protein
concentrated in Centrikon-30 concentrators (Amicon Corp.,
Easton, TX).
4.3 Cell death assays
Kym-1 cells (1 × 104 per well) were cultivated in 96-well
microtiter plates overnight. The next day TWEAK-FLAG,
TWEAK-FLAG-M2-complex (M2 constant 0.5 ? g/ml) and/or
antibodies were applied as indicated and after additional
18 h of culture metabolic activity was measured by the 3[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
method.
4.4 EMSA analysis of NF- B B activation
Kym-1 cells (106) were seeded in 60-mm cell culture dishes
and cultivated overnight. The next day the cells were stimu-
lated for various times with the indicated combinations of
TNF and TWEAK. Preparation of nuclear extracts was
described elsewhere [29] and electrophoretic mobility shift
assays (EMSA) were performed using a standard procedure
using a HPLC-purified NF- O B-specific oligonucleotide (5’-
ATC AGG GAC TTT CCG CTG GGG ACT TTC CG-3’), end-
labeled with [ + -32P]ATP.
4.5 Immune complex JNK assay
Immune complex JNK assays were essentially performed as
described elsewhere [33]. In brief, 106 Kym-1 cells were
seeded in 60-mm cell culture dishes and cultivated over-
night. The next day cells were stimulated as indicated, har-
vested with a rubber policeman, washed once with PBS and
lysed in 1 ml of kinase lysis buffer [200 mM Tris, pH 7.4;
5 mM MgCl2, 1 % Triton X-100, 150 mM NaCl, 0.1 mM
phenylmethylsulfonylfluoride (PMSF); 1 ? g/ml leupeptin,
2 mM Na3VO4 and 10 mM NaF] for 20 min on ice. Cell debris
was removed by centrifugation at 10 000 × g for 10 min at
4 °C. JNK was immunoprecipitated with 0.5 ? g of a rabbit
polyclonal anti-JNK antiserum (Santa Cruz Biotechnology)
and 20 ? l protein A-Sepharose beads for 2 h. Beads were
washed three times with kinase lysis buffer and twice in
assay buffer (20 mM MOPS, pH 7.2; EGTA 10 mM; 10 mM
MgCl2, 0.1 % Triton X-100 and 1 mM DTT). Beads were left in
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a 1:1 suspension and kinase reactions were started by addi-
tion of 0.5 ? g GST-jun(1-79) and ATP (100 ? M ATP and 5 ? Ci
[ + -32P]ATP). After incubation for 20 min at room temperature
reactions were stopped by adding 25 ? l sixfold concentrated
Laemmli buffer and boiling for 5 min. Finally samples were
resolved on an SDS-polyacrylamide gel, transferred to nitro-
cellulose and analyzed using a phosphorimager.
4.6 Western blotting
Cells were sonicated in PBS containing a mix of protease
inhibitors (Complete TM, Roche Molecular Biochemicals,
Rotkreuz, Switzerland) and centrifuged for 10 min at
10 000 × g. Lysates and pellets were heated (5 min, 95 °C) in
PNGaseF denaturation buffer (1 % 2-ME and 0.5 % SDS),
then supplemented with 1 % NP40 and 50 mM sodium phos-
phate pH 7.5 and digested for 1 h with or without 100 U of
PNGaseF. Subsequently proteins were separated by SDS-
PAGE and transferred to nitrocellulose. Apo3/TRAMP was
detected with anti-TRAMP antibodies (50 ng/ml) followed by
peroxidase-labeled goat anti-rabbit antibodies (1.4000 dilu-
tion, Jackson Immunoresearch, West Grove, PA).
4.7 RNase protection assays
RNA was isolated from Kym-1 cells with RNA INSTAPURE
(Eurogentech, Belgium) according to the manufacturer’s rec-
ommendations. Subsequently, RNase protection assays
were performed with the hAPO-3c Multi-Probe template set
(PharMingen, Hamburg, Germany) containing probes for
caspase-8, FasL, Fas DcR1, DR3, DR4, DR5, TRAIL, TNFR1,
TRADD, RIP and L32 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) internal controls. Probe synthesis,
hybridization and RNase treatment were performed with the
RiboQuant Multi-Probe RNase Protection Assay System
(PharMingen, Hamburg, Germany) according to the manu-
facturer’s recommendations. Samples were resolved by
electrophoresis on denaturing polyacrylamide gels (5 %) and
quantified by phosphorimaging.
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